Bristol-Myers Squibb Co. (NYSE:BMY)

Prescription drugs

Short Sellers Run For Cover From Major Pharma

The short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

Why Bristol-Myers Squibb Solid Earnings Beat Failed to Impress

Bristol-Myers Squibb Co. (NYSE: BMY) released its second-quarter financial results before the markets opened Thursday. The major pharmaceutical firm had $0.53 in earnings per share (EPS) on revenue of $4.2 ...
Read Full Story »
Pills

Short Sellers Run for Cover in Big Pharma

The short interest data have been released for the June 30 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Pills

Is Big Pharma Advertising Getting Out of Control?

How much are big pharmaceutical companies really spending to get their drugs out there in the public eye? In 2014, these companies spent about $4.5 billion in advertising alone, notably ...
Read Full Story »
Pills

Short Sellers Become More Focused on Big Pharma

The short interest data has been released for the June 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

Short Sellers Back Off Big Pharma

The short interest data has been released for the May 29 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Credit Suisse sees some solid upside in big pharma in the coming years. After the health care sector has made a strong run, this firm believes that it can continue, ...
Read Full Story »
generic drugs

The 4 Overlooked Winners of ASCO

The American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to share ...
Read Full Story »
Pills

Short Sellers More Selective on Big Pharma Stocks

The short interest data has been released for the May 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

Short Sellers Keep Strong Bets Against Big Pharma

The short interest data has been released for the April 30 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
465448648

4 Pharmaceutical Companies Leading the Breast Cancer Fight

If one cancer strikes a chord with women all over the world, it is breast cancer. While treatments have improved dramatically, it still ranks as the most common cancer among ...
Read Full Story »
Prescription drugs

Top Credit Suisse Major Pharma Stock Picks to Buy

Considering the health care sector has been on fire for the first quarter of 2015, analysts are putting more value in biotechs and big pharmaceuticals. Credit Suisse is no different. ...
Read Full Story »
health care

Will Schizophrenia and Bipolar Patients Trust Generic Abilify?

The trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: GE, IBM, Bristol-Myers, Encana, Halliburton, Rio Tinto, WhiteWave and More

Stocks were indicated up on Tuesday, even after Monday's big gains. The trend that is nearing four years old now is that investors keep buying stocks on weakness. 24/7 Wall ...
Read Full Story »
Pills

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »